Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2010, 3(7), 2022-2044; doi:10.3390/ph3072022
Review

Demethylating Agents in the Treatment of Cancer

Jr.
,
 and *
Received: 4 May 2010; in revised form: 22 June 2010 / Accepted: 29 June 2010 / Published: 2 July 2010
(This article belongs to the Special Issue Targeted Therapy)
View Full-Text   |   Download PDF [157 KB, uploaded 2 July 2010]
Abstract: Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies. Two demethylating agents, azacitidine and decitabine, are approved for the treatment of myelodysplastic syndromes (MDS) by the U.S. Food and Drug Administration (FDA), and are now considered the standard of care in MDS. In this review, we discuss clinical data, including clinical benefits and toxicities, which led to the approval of azacitidine and decitabine. We also summarize findings from clinical trials that used these two demethylating agents in the treatment of solid tumors. Lastly, we discuss some limitations in the use of azacitidine and decitabine in cancer therapy.
Keywords: azacitidine; cancer; decitabine; epigenetics; methylation azacitidine; cancer; decitabine; epigenetics; methylation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Howell, P.M., Jr.; Liu, Z.; Khong, H.T. Demethylating Agents in the Treatment of Cancer. Pharmaceuticals 2010, 3, 2022-2044.

AMA Style

Howell PM, Jr, Liu Z, Khong HT. Demethylating Agents in the Treatment of Cancer. Pharmaceuticals. 2010; 3(7):2022-2044.

Chicago/Turabian Style

Howell, Paul M., Jr.; Liu, Zixing; Khong, Hung T. 2010. "Demethylating Agents in the Treatment of Cancer." Pharmaceuticals 3, no. 7: 2022-2044.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert